We were very pleased that a combination that we believe has strong potential to build upon the responses seen in the initial CORE-NK clinical trial was rapidly identified. CHM 0201 will be studied in combination with Vactosertib and IL-2. Vactosertib is an oral TGF-β receptor inhibitor that can potentially disrupt the TGF-β signaling pathway, which has been shown to limit the effectiveness of immune therapies like NK cells while IL-2 is known to activate NK cells by stimulating proliferation and enhancing function.
This is another way of getting the "protective shields" crashed which cancer cells use to protect themselves against the immune system. Like IMU's B-cell technology, clearing the way for the immune system to attack, kill and very importantly, to hopefully "Memorise" the process for an everlasting protection.
Hi 7.7c seller. Looks like you and me are filling each other's orders. You're selling, I am buying. Let's see who is doing the smarter thing. I hope it's me.
GLTA
CHM Price at posting:
7.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)